About Wells Therapeutics Inc.
We advance innovative, early-stage assets from China into world-class breakthrough therapies through a hybrid U.S.–China operational model. By combining deep clinical expertise with efficient execution, we accelerate Proof-of-Concept (PoC) development with exceptional speed and cost effectiveness.
​
Our mission is to bring transformative therapies to patients worldwide while creating strong investor value through disciplined in-licensing, accelerated development pathways, and strategically optimized exits.
Our Return
Deliver clinical PoC data as value driver in record speed (within 2-3 years from product initiation) with capital return efficiency
Exit - Aligned Development
Align clinical development to M&C acquisition criteria
Capital Efficiency
Flexible BD deal structures (hybrid model with lower upfront cost) combined with China cost advantages
Investment Thesis
Our "Dual-Hemisphere" strategy for rapid, high-value biotechnology exits
The Opportunity
​China's biotech produce high-quality, cost-effective early-stage assets at unprecedented speed, but lack global vision and clinical expertise to drive for global leadership.
Our Solution
Apply U.S. led clinical strategies and a China operation for on-the-ground collaboration, delivering Phase 1/2 PoC data for high-value exits.
Our Unique Edge
True "dual-hemisphere" advantage that cannot be easily replicated.
Esteemed Global Team + China Operation
Local Culture & Business Insights
Strategic Consulting and Business Development
We bridge the gap between breakthrough science and commercial success, offering unparalleled expertise to scale biotech enterprises.
Consulting Services
Designed to empower partners to navigate the "Value vs. Risk" landscape of the Chinese clinical market. Much like our Life Sciences Advisory, these services transform China’s unique operational environment into a strategic advantage, leveraging our deep local expertise to ensure trials meet global standards while maximizing efficiency
Business Development Advisory
Wells Therapeutics Inc. life sciences advisory bridges pharmaceutical innovation between China and the United States through three integrated platforms, built on decades of cross-border clinical development excellence from Pfizer, Takeda, Novartis, GSK, Roche, Bayer, and AbbVie.
Rooted in Science.
Driven by Business.
Our foundation is deeply scientific. We understand the technical milestones, regulatory pathways, and clinical hurdles that define success in biotech. This dual expertise in science and business mitigates risk for our investors.
Scientific Integrity
Rigorous evaluation of drug mechanisms, preclinical data quality, and translational potential to identify truly innovative therapeutic approaches with validated proof-of-concept.
Expert Network
Access to leading KOLs, clinical advisors, and industry veterans across China and global markets, enabling strategic partnerships and accelerated regulatory navigation.